|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rivaroxaban( BAY 59-7939) an oral direct factor Xa inhibitor has nolinically relevant interaction with naproxen 显示文摘 | Kubitza D Michaell B Wolfgang M | 2007 | Br J Clin Pharm2007，4，63： | 1 |
| 2 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7959 ) in heahhy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 3 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | | 0，，： | 1 |
| 4 | Safety, tolerability, phar- macodynamics, and pharmacokinetics of rivaroxaban-an oral, di- rect Factor Xa inhibitor-are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 5 | No interaction between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Phann2006，46，3： | 1 |
| 6 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor in healthy subjects显示文摘 | Mueck W Beeka M Kubitza D | | 0，，： | 1 |
| 7 | ICAM-1 and VCAM-1 expression following aneurysmal subarach- noid hemorrhage and their possible role in the pathophysi- ology of subsequent ischemic deficits 显示文摘 | Rothoerl RD Schebesch KM Kubitza M | 2006 | Cerebrovasc Dis2006，22，23： | 1 |
| 8 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 9 | ICAM-1 andVCAM-1expression following aneurysmal subarachniod hemorrhageand their possible role in the pathopysiology of subsequent ischmicdeficits显示文摘 | Rothoer RD Schebesch KM Kubitza M | 2006 | Cerebrovasc Dis2006，22，23： | 1 |
| 10 | ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic defioits显示文摘 | Rothoerl RD Schebesch KM Kubitza M | 2006 | Cerebrovasc Dis2006，22，23： | 1 |
| 11 | Safety, pharmaco- dynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor X a inhibitor--after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，： | 1 |
| 12 | Safety, tolerabil- ity, pharmacodynamics, and pharmacokinetics of rivaroxa- ban--an oral, direct factor Xa inhibitor--are not affected by aspirin 显示文摘 | KUBITZA D BECKA M MUECK W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 13 | Safety, pharmaco- dynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor X a inhibitor 显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 14 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban -- an oral direct factor Xa inhibitor -- in healthy subjects 显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，33： | 1 |
| 15 | Safety, pharma- codynamics, and pharmacokinetics of BAY 59-7939 an o- ral, direct factor X a inhibitor - after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，12： | 1 |
| 16 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban ( BAY 59-7939 ) in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 17 | Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，12： | 1 |
| 18 | Rivaroxaban(BAY 59-7939)-an oral,direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen 显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmacol2007，63，4： | 1 |
| 19 | Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice显示文摘 | Schon M Denzer D Kubitza RC | 2000 | J Invest Dermatol2000，14，5： | 1 |
| 20 | Rivaroxaban (BAY 59-7939)-anoral,direct factor xa inhibitor-has no clinically relevant interaction with naproxen显示文摘 | Kubitza D Becka M Mueck W | 2007 | Br J Clin Pharmaeol2007，63，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员